Atrial Fibrillation at Discharge From the Hospital in Patients Undergoing Mitral Valve Repair

Abstract

Background: Patients undergoing mitral valve repair (MVRr) are often discharged on oral anticoagulation with warfarin. Because the decision about oral anticoagulation is made at discharge from the hospital and because atrial fibrillation (AF) represents the only well-documented indication for oral anticoagulation in these patients, we studied the frequency of AF at discharge after MVRr. Methods: We reviewed the records of 245 patients who underwent MVRr over the past 5 years and assessed the frequency of AF at discharge from the hospital and the factors that were associated with an increased risk for arrhythmia. Results: The group comprised 95 women and 150 men with a mean age of 62.1 ± 14 years. Seventy-three (30 %) patients were in and/or had a history of AF on admission. Sixty-five (27 %) patients had AF at discharge. Factors that were associated with AF at discharge were: AF on admission (odds ratio [OR] 57.1; confidence interval [CI] 20.8 - 157.3; p < 0.0001), enlarged left atrium (OR 3.2; CI 1.2 - 8.7; p = 0.025) and intake of ACE inhibitors (OR 3.9; CI 1.2 - 12.3; p = 0.022). The OR for AF at discharge in patients with none of the above risk factors was 0.02 (95 % CI 0.02 - 0.13; p < 0.0001). Conclusion: Only a relatively small proportion of the studied patients, especially patients with AF on admission, with larger atria and with a history of ACE inhibitors intake, were in AF at discharge after MVRr. Patients with none of these risk factors were at low risk for AF at discharge after MVRr and the optimal oral anticoagulation regimen for these low-risk patients needs to be determined.

Key words

Mitral valve - atrial fibrillation - anticoagulants - risk factors - atrial enlargement - ACE inhibitors

References

• 1 Hahn C, Vlahakes G J. Nonreplacement operations for mitral valve regurgitation.  Annu Rev Med. 1997;  48 295-306
• 2 The Society of Thoracic Surgeons .National Database Spring 2002 Executive Summary. www.sts.org . 8.10.2002
• 3 Almassi G H, Schowalter T, Nicolosi A C, Aggarwal A, Moritz T E, Henderson W G, Tarazi R, Shroyer A L, Sethi G K, Grover F L, Hammermeister K E. Atrial fibrillation after cardiac surgery: A major morbid event?.  Ann Surg. 1997;  226 501-513
• 4 Kannel W B, Wolf P A, Benjamin E J, Levy D. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: Population based estimates.  Am J Cardiol. 1998;  82 2-9
• 5 Benjamin E, Levy D, Varizi S, Dágostino R E, Ralph B, Belanger A, Wolf P. Independent risk factors for atrial fibrillation in a population based cohort: The Framingham Heart Study.  JAMA. 1994;  271 840-844
• 6 Gohlke-Bärwolf C. Anticoagulation in valvar heart disease: new aspects and management during non cardiac surgery.  Heart. 2000;  84 567-572
• 7 Obadia J F, el Farra M, Bastien O H, Lievre M, Martelloni Y, Chassignolle J F. Outcome of atrial fibrillation after mitral valve repair.  J Thorac Cardiovasc Surg. 1998;  115 179-185
• 8 Heras M, Chesbro J, Fuster V, Penny W J. High risk of thromboemboli early after bioprosthetic cardiac valve replacement.  J Am Coll Cardiol. 1995;  25 1111-1119
• 9 Lim E, Barlow C, Hosseinpour R, Wisbey C, Wilson K, Pidgeon W, Charman S, Barlow J B, Wells F C. Influence of atrial fibrillation on outcome following mitral valve repair.  Circulation. 2001;  104 59-63
• 10 Vogt P R, Brunner-La Rocca H P, Rist M, Zünd G, Genoni M. Preoperative predictor of recurrent atrial fibrillation late after successful mitral valve reconstruction.  Eur J Cardiothoracic Surg. 1998;  13 619-624
• 11 Goldsmith I R, Blann A D, Andrew D, Patel R L, Lip G Y. Von Willebrand factor fibrinogen, and soluble P selectin levels after mitral valve replacement versus valve repair.  Am J Cardiol. 2000;  85 1218-1288
• 12 Bonow R O, Carabello B, De Leon Jr A C, Edmunds Jr L H, Fedderly B J, Freed M D, Gaasch W H, McKay C R, Nishimura R A, O'Gara P T, O'Rourke R A, Rahimtoola S H, Ritchie J L, Cheitlin M D, Eagle K A, Gardner T J, Garson Jr A, Gibbsons R J, Russell R P, Ryan T J, Smith Jr S C. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease).  Circulation. 1998;  98 1949-1984
• 13 Tiede D J, Nishimura R A, Gastineau D A, Mullany C J, Orszulak T A, Schaff H V. Modern management of prosthetic valve anticoagulation.  Mayo Clin Proc. 1998;  73 665-680
• 14 Armamendi J L, Agredo J, Llorente A, Larrarte C, Pijoan J. Prevention of thromboembolism with ticlopidine shortly after valve repair or replacement with a bioprosthesis.  J Heart Valve Dis. 1998;  7 611-614
• 15 Brandt R R, Neumann T, Neuzner J, Rau M, Faude I, Hamm C W. Transcatheter closure of atrial septal defect and patent foramen ovale in adult patients using the Amplatzer occlusion device: No evidence for thrombus deposition with antiplatelet agents.  J Am Soc Echocardiogr. 2002;  15 1094-1098
• 16 Enriquez-Sarano M, Orszulak T, Schaff H V, Abel M D, Tajik A J, Frye R L. Mitral reurgitation: A new clinical perspective.  Mayo Clin Proc. 1997;  72 1034-1048
• 17 Pedersen O D, Bagger H, Kober L. et al . Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.  Circulation. 1999;  100 376-380
• 18 Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodelling in atrial fibrillation.  Circulation. 2000;  101 2612-2617
• 19 Naccarella F, Naccarelli G V, Maranga S S, Lepera G, Grippo M C, Melandri F, Gatti M, Pazzaglia S, Spinelli G, Angelini V, Ambrosioni E, Borghi C, Giovagnorio M T, Nisam S. Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials.  Curr Opin Cardiol. 2002;  17 6-18
• 20 Onnasch J F, Schneider F, Mierzwa M, Mohr F W. Mitral valve repair versus mitral valve replacement.  Z Kardiol. 2001;  90 75-80